InflaRx N.V. (IFRX)
| Market Cap | 297.68M +248.7% |
| Revenue (ttm) | -11,540 -82.3% |
| Net Income | -44.72M |
| EPS | -0.54 |
| Shares Out | 147.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 579,600 |
| Open | 2.120 |
| Previous Close | 2.120 |
| Day's Range | 1.990 - 2.165 |
| 52-Week Range | 0.798 - 2.949 |
| Beta | 2.54 |
| Analysts | Strong Buy |
| Price Target | 7.92 (+292.08%) |
| Earnings Date | Aug 6, 2026 |
About IFRX
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its u... [Read more]
Financial Performance
In 2025, InflaRx's revenue was 29,331, a decrease of -82.31% compared to the previous year's 165,789. Losses were -45.63 million, -0.93% less than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for IFRX stock is "Strong Buy." The 12-month stock price target is $7.92, which is an increase of 292.08% from the latest price.
News
InflaRx Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A strategic shift to renal diseases, especially ANCA vasculitis, is supported by strong clinical data and a favorable safety profile for the lead candidate, izicopan. The withdrawal of a key competitor in Europe has created a major market opportunity, and recent financing ensures funding through 2029.
InflaRx initiated with a Buy at Needham
Needham initiated coverage of InflaRx (IFRX) with a Buy rating and $8 price target InflaRx’s izicopan offers potentially significant upside in ANCA-associated vasculitis as a next-generation oral C5aR...
InflaRx Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
A strategic pivot prioritizes ANCA vasculitis with INF904, designed for better safety and efficacy, and vilobelimab as a bridging option amid competitor withdrawals. Regulatory engagement is active, with phase II trials set to begin early next year and broader renal indications under consideration.
InflaRx Announces Participation in September Investor Conferences
Jena, Germany, Aug. 20, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced...
InflaRx Earnings release: Q2 2026
InflaRx released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
InflaRx files $250M mixed securities shelf
09:22 EDT InflaRx (IFRX) files $250M mixed securities shelf
InflaRx Registration statement: Registration filing
InflaRx filed a registration statement on August 6, 2026, providing details about a securities offering with the SEC.
InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as planned Initiated feasibility assessment for broadened strategy for AA...
InflaRx to Report Second Quarter 2026 Results on August 6, 2026
Jena, Germany, July 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced...
InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced...
InflaRx upgraded to Strong Buy from Outperform at Raymond James
Raymond James upgraded InflaRx (IFRX) to Strong Buy from Outperform with a price target of $9, up from $7. Following Q1 earnings, sentiment is increasingly supported by a constructive view…
InflaRx price target raised to $8 from $6 at H.C. Wainwright
H.C. Wainwright analyst Matthew Keller raised the firm’s price target on InflaRx (IFRX) to $8 from $6 and keeps a Buy rating on the shares based on the company’s adjusted…
InflaRx Transcript: Investor update
Izicopan is being advanced as a differentiated oral C5aR inhibitor for AAV and other renal diseases, with a strong safety profile, rapid onset, and potential for once-daily dosing. Clinical trials are designed to demonstrate early efficacy and safety, with regulatory engagement and market expansion strategies underway.
InflaRx Press release: Investor update
InflaRx issued a press release on May 8, 2026, disclosing material business information to investors.
InflaRx Slides: Investor update
InflaRx has posted slides in relation to its latest quarterly earnings report, which was published on May 8, 2026.
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
Jena, Germany, May 08, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, ann...
InflaRx to develop izicopan in AAV
InflaRx (IFRX) announced that it intends to develop izicopan, an oral C5a receptor inhibitor, in AAV, a life-threatening kidney disorder. InflaRx is conducting Phase 2 planning for izicopan in AAV…
InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares
Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, anno...
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...
InflaRx announces new izicopan pre-clinical data
InflaRx (IFRX) announced new pre-clinical data demonstrating low reactive metabolite formation of izicopan in human liver microsomes. Reactive metabolite formation is widely used in drug development a...
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
JENA, Germany, May 04, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced n...
InflaRx to Report First Quarter 2026 Results on May 7, 2026
JENA, Germany, May 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced t...
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
JENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company”),...
InflaRx assumed with an Outperform at Oppenheimer
Oppenheimer analyst Mazahir Alimohamed assumed coverage of InflaRx (IFRX) with an Outperform rating with a price target of $5, down from $7. The firm views izicopan, an oral C5aR inhibitor…
InflaRx announces new izicopan in vitro findings
InflaRx (IFRX) announced new in vitro findings demonstrating that izicopan does not exhibit time-dependent inhibition of CYP3A4, an important indicator for the risk for drug-drug interactions and live...